Wells Fargo & Company MN Sells 4,744 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Wells Fargo & Company MN cut its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 51,735 shares of the company’s stock after selling 4,744 shares during the quarter. Wells Fargo & Company MN owned about 0.05% of Day One Biopharmaceuticals worth $655,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. ExodusPoint Capital Management LP bought a new position in Day One Biopharmaceuticals in the fourth quarter valued at approximately $2,726,000. Trexquant Investment LP acquired a new position in Day One Biopharmaceuticals in the 4th quarter worth $1,115,000. Geode Capital Management LLC boosted its stake in Day One Biopharmaceuticals by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 1,462,982 shares of the company’s stock worth $18,541,000 after purchasing an additional 30,285 shares during the period. Franklin Resources Inc. increased its holdings in Day One Biopharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company’s stock worth $49,197,000 after purchasing an additional 13,320 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Day One Biopharmaceuticals by 1.3% in the 4th quarter. Wellington Management Group LLP now owns 731,303 shares of the company’s stock valued at $9,266,000 after purchasing an additional 9,722 shares during the period. 87.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This represents a 10.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the sale, the chief executive officer now owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,064 shares of company stock valued at $251,925. 6.20% of the stock is owned by insiders.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $7.62 on Friday. The company has a fifty day moving average price of $8.00 and a two-hundred day moving average price of $11.43. Day One Biopharmaceuticals, Inc. has a one year low of $6.41 and a one year high of $18.00. The stock has a market cap of $772.32 million, a P/E ratio of -7.40 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million. As a group, equities research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DAWN. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Bank of America decreased their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Finally, JPMorgan Chase & Co. cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $32.29.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.